April 7, 2025 — CardioVia, a medical device company specializing in advanced cardiac care solutions, has received U.S. Food and Drug Administration (FDA) clearance for its ViaOne system. This device is designed to enable safe and precise access to the heart’s surface (pericardial space) for both diagnostic and therapeutic interventions — without using an exposed needle. By eliminating the need for an uncontrolled sharp needle, ViaOne mitigates the risk of heart perforation, a well-recognized complication associated with current percutaneous techniques.

April 4, 2025 — Viz.ai has been named an Award Winner in the 2025 Edison Awards, for the third year in a row.

April 3, 2025 — Tower Health and Siemens Healthineers  recently announced a 10-year agreement focused on equipment enhancement, technology modernization and improving clinical experience for patients. This Value Partnership1 will bring comprehensive improvements in diagnostic imaging and digital intelligence tools to cardiology, radiology and oncology across the Tower Health system.

Tower Health is a regional integrated healthcare system that offers compassionate, high-quality, leading-edge healthcare and wellness services to communities in Pennsylvania.

March 31, 2025 — Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronary artery disease than conventional angiography, the more commonly used technique.

March 29, 2025 — Anthos Therapeutics, Inc., presented two new analyses from its AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session (ACC.25) demonstrating the novel Factor XI inhibitor abelacimab significantly reduced bleeding in patients regardless of age or bleeding risk. 

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.

March 31, 2025 —  iRhythm Technologies, Inc. has announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago.

March 31, 2025 — AGEPHA Pharma USA, LLC, has highlighted clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease.

Mar. 28, 2025 — At the American College of Cardiology (ACC) 2025 meeting, GE HealthCare will introduce Revolution Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now